by Maria Zannes | Oct 30, 2024 | Press Releases
SAN ANTONIO, Texas (Oct. 30, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent...
by Maria Zannes | Oct 18, 2024 | Press Releases
SAN ANTONIO, TX (Oct. 18, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with...
by Maria Zannes | Oct 16, 2024 | Articles, News
As published in Mergermarket By Deborah Balshem and Jeff Sheban Summary • Medicare reimbursement providing tailwinds • Expansion into government market imminent • Analyst sees labs chains among potential buyers bioAffinity Technologies [NASDAQ:BIAF], a healthcare...
by Maria Zannes | Oct 16, 2024 | Press Releases
bioAffinity VP served on expert panel that published new guidance SAN ANTONIO, TX (Oct. 16, 2024) – bioAffinity Technologies’ (Nasdaq: BIAF) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the...
by Maria Zannes | Oct 13, 2024 | Articles, News
With a San Antonio biotech firm’s test, your phlegm could help save you from cancer. As published by the San Antonio Express-News By Brandon Lingle, Staff Writer The screening method developed by bio Affinity Technologies Inc. uses Al-aided computer analysis...
